Q4/FY 2022 Financial Results and Business Update March 22, 2023 Confidential 1 Forward Looking Statements Thispresentationandvariousremarkswemakeduringthispresentationcontainforward-lookingstatementswithinthemeaningofapplicablesecuritieslawsandregulationsincluding,butnotlimitedto,statements regarding: expectationsregardingthepotentialsignificanceofthepreliminaryandinitialresultsfromthePhase1aSTAR-0215trialandtheanticipatednatureandtimingofreceiptofthedatafromthetwoadditional cohortsinsuchtrial;expectationsr ...

Table of Contents or UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37467 Astria Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 26-3687168 (State or ...

Astria Therapeutics, Inc. (NASDAQ:ATXS) Q3 2021 Earnings Conference Call November 10, 2021 8:30 AM ET Company Participants Andrea Matthews - Senior Vice President, Corporate Affairs Jill Milne - Chief Executive Officer Andy Nichols - Chief Scientific Officer Andrew Komjathy - Chief Commercial Officer Noah Clauser - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Suji Jeong - Jefferies Laura Chico - Wedbush Securities Joe Pantginis - H.C. Wainwright Operator Good day and thank ...